FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal By Ogkologos - June 20, 2025 751 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with... November 5, 2025 What’s happened to cancer services during the COVID-19 pandemic? September 11, 2020 High Risk of BCSM at 20 Years in Men with Hormone... March 1, 2024 Patients with Early Stage NSCLC Have a Higher TMB in Comparison... October 9, 2020 Load more HOT NEWS New study to detect oesophageal cancer earlier New ESMO President 2029-2030 Elected Cancer in My Community: Caring for the Whole Patient in Brazil How Exercise Can Help You Cope With the Mental and Emotional...
